Dimas Padilla thought he was dying for sure.
He’d been through the wringer with a type of blood cancer called non-Hodgkin’s lymphoma. First, he tried chemotherapy, and then, when the cancer came back a year and a half later, he underwent a bone marrow transplant.
But last year, when it came back again, he believed he was out of options.
“I was losing my battle against cancer,” Padilla, a 43-year-old sales representative, told NBC News.
Then he found out about an experimental therapy that’s a step beyond bone marrow transplants.
Called chimeric antigen receptor T-cell therapy — CAR-T for short — it involves taking a samples of T-immune cells called T-cells from a patient, genetically engineering them, and putting them back in to fight the cancer.
Continue to the original article…